Use of Steroidal Antiinflammatory Drug Provides Further Evidence for a Potential Role of PAF-Acether in Bronchial Anaphylaxis
- 1 January 1986
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 81 (2) , 184-185
- https://doi.org/10.1159/000234130
Abstract
We presently demonstrate that PAF-acether (1-O-alkyl-2–O-acetyl-sn-glycerol-3-phosρhoryl-choline) is formed by sensitized guinea pig lungs upon in vitro antigenic challenge. Pretreatment of the animals with a steroidal antiinflammatory drug, budesonide, almost totally suppresses this biosynthesis. Since budesonide inhibits the anaphylactic bronchoconstriction in actively sensitized guinea pigs, these data strongly support the assumption that PAF-acether is a mediator of bronchial anaphylaxis.This publication has 4 references indexed in Scilit:
- Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE.The Journal of Immunology, 1983
- Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients.Journal of Clinical Investigation, 1983
- Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivativesEuropean Journal of Pharmacology, 1980
- Antigen‐Induced Bronchial Anaphylaxis in Actively Sensitized Guinea‐Pigs Pattern of Response in Relation to Immunization RegimenAllergy, 1980